An international online platform, Made-in-China, has reached a settlement with the Connecticut attorney general’s office to stop the sale of GLP-1 weight-loss medications to U.S. customers. The platform previously marketed these products as generic versions of popular name-brand drugs like Ozempic, Mounjaro, Wegovy, and Zepbound, often without requiring any prescriptions or oversight.
Authorities found that these so-called research grade medications posed significant health risks. Laboratory analysis revealed that the products frequently contained impurities, potential bacterial contamination, and inconsistent levels of active ingredients. These issues led to concerns about accidental overdoses and other dangerous side effects for consumers who purchased the drugs online.
Connecticut Attorney General William Tong confirmed that no generic GLP-1 injections are currently legal for sale on the market. He warned that any entity advertising such products is misrepresenting the safety of the medication and endangering public health. This enforcement action highlights a broader move by state regulators to curb the availability of bootleg weight-loss injections that have gained popularity alongside the increased usage of legitimate prescribed therapies.
As part of the settlement agreement, the platform must implement a system to monitor and remove any future listings for GLP-1 drugs within five days. The company has also agreed to a penalty of $300,000, which will remain suspended after an initial $30,000 payment. The office stated that it will continue active enforcement efforts to shut down similar illegal sales channels and protect patients from unregulated imports.